Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anne Catherine Bretz

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Cancer Letters|September 10, 2011
Targeting p73 in cancerAnna-Maria Maas, Anne Catherine Bretz, Elisabeth Mack, et al.
Nucleic Acids Research|February 13, 2008
C-terminal diversity within the p53 family accounts for differences in DNA binding and transcriptional activityMarkus Sauer, Anne Catherine Bretz, Rasa Beinoraviciute-Kellner, et al.
Hemasphere|May 6, 2022
The Nuclear Proteins TP73 and CUL4A Confer Resistance to Cytarabine by Induction of Translesion DNA Synthesis via Mono-ubiquitination of PCNAMiriam Rehberger, Jonas A Schäfer, Anna-Maria Krampitz, et al.
Journal for Immunotherapy of Cancer|November 10, 2019
Domatinostat favors the immunotherapy response by modulating the tumor immune microenvironment (TIME)Anne Catherine Bretz, Ulrike Parnitzke, Kerstin Kronthaler, et al.
The Journal of Investigative Dermatology|October 1, 2020
The HDAC Inhibitor Domatinostat Promotes Cell-Cycle Arrest, Induces Apoptosis, and Increases Immunogenicity of Merkel Cell Carcinoma CellsLina Song, Anne Catherine Bretz, Jan Gravemeyer, et al.
The EMBO Journal|February 2, 2008
p73 poses a barrier to malignant transformation by limiting anchorage-independent growthMichaela Beitzinger, Lars Hofmann, Claudia Oswald, et al.
Nucleic Acids Research|January 29, 2016
ΔNp63 activates the Fanconi anemia DNA repair pathway and limits the efficacy of cisplatin treatment in squamous cell carcinomaAnne Catherine Bretz, Miriam P Gittler, Joël P Charles, et al.
Nature Chemical Biology|November 24, 2015
CRISPR-Cas9-based target validation for p53-reactivating model compoundsMichael Wanzel, Jonas B Vischedyk, Miriam P Gittler, et al.
Blood Neoplasia|August 1, 2025
Dose escalation study of the HLA-A2-WT1 CD3 bispecific antibody RO7283420 in relapsed/refractory acute myeloid leukemiaMartin Hutchings, Koorosh Korfi, Pau Montesinos, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Cancer Letters|September 10, 2011
Targeting p73 in cancerAnna-Maria Maas, Anne Catherine Bretz, Elisabeth Mack, et al.
Nucleic Acids Research|February 13, 2008
C-terminal diversity within the p53 family accounts for differences in DNA binding and transcriptional activityMarkus Sauer, Anne Catherine Bretz, Rasa Beinoraviciute-Kellner, et al.
Hemasphere|May 6, 2022
The Nuclear Proteins TP73 and CUL4A Confer Resistance to Cytarabine by Induction of Translesion DNA Synthesis via Mono-ubiquitination of PCNAMiriam Rehberger, Jonas A Schäfer, Anna-Maria Krampitz, et al.
Journal for Immunotherapy of Cancer|November 10, 2019
Domatinostat favors the immunotherapy response by modulating the tumor immune microenvironment (TIME)Anne Catherine Bretz, Ulrike Parnitzke, Kerstin Kronthaler, et al.
The Journal of Investigative Dermatology|October 1, 2020
The HDAC Inhibitor Domatinostat Promotes Cell-Cycle Arrest, Induces Apoptosis, and Increases Immunogenicity of Merkel Cell Carcinoma CellsLina Song, Anne Catherine Bretz, Jan Gravemeyer, et al.
The EMBO Journal|February 2, 2008
p73 poses a barrier to malignant transformation by limiting anchorage-independent growthMichaela Beitzinger, Lars Hofmann, Claudia Oswald, et al.
Nucleic Acids Research|January 29, 2016
ΔNp63 activates the Fanconi anemia DNA repair pathway and limits the efficacy of cisplatin treatment in squamous cell carcinomaAnne Catherine Bretz, Miriam P Gittler, Joël P Charles, et al.
Nature Chemical Biology|November 24, 2015
CRISPR-Cas9-based target validation for p53-reactivating model compoundsMichael Wanzel, Jonas B Vischedyk, Miriam P Gittler, et al.
Blood Neoplasia|August 1, 2025
Dose escalation study of the HLA-A2-WT1 CD3 bispecific antibody RO7283420 in relapsed/refractory acute myeloid leukemiaMartin Hutchings, Koorosh Korfi, Pau Montesinos, et al.
Pageof 1